Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial

被引：0

作者：

Humrich, Jens ^{[1
]}

von Spee-Mayer, Caroline ^{[2
]}

Siegert, Elise ^{[3
]}

Rose, Angelika ^{[2
]}

Bertolo, Martina ^{[4
]}

Enghard, Philipp ^{[5
]}

Hiepe, Falk ^{[6
]}

Alexander, Tobias ^{[3
]}

Feist, Eugen ^{[6
]}

Radbruch, Andreas ^{[7
]}

Burmester, Gerd R. ^{[6
]}

Riemekasten, Gabriela ^{[8
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dept Rheumatol, Campus Lubeck, Lubeck, Germany

[2] Charite, Rheumatol & Clin Immunol, Berlin, Germany

[3] Charite Univ Med Berlin, Rheumatol & Clin Immunol, Berlin, Germany

[4] Charite Univ Med Berlin, Dept Rheumatol, Berlin, Germany

[5] Charite Univ Med Berlin, Dept Nephrol, Berlin, Germany

[6] Charite, Berlin, Germany

[7] Deutsch Rheumaforschungszentrum, Berlin, Germany

[8] Univ Klinikum Schleswig Holstein, Dept Rheumatol, Lubeck, Germany

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

13L

引用

页数：3

共 50 条

[31] Low-Dose Radiation Therapy with Nivolumab in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of the Phase II Radvax Trial
LaRiviere, Michael J.
Vaziri, Tina
Farwell, Michael
Maity, Amit
Paydar, Ima
Schuster, Stephen J.
Nasta, Sunita Dwivedy
Chong, Elise A.
Landsburg, Daniel J.
Plastaras, John P.
Svoboda, Jakub
[J]. BLOOD, 2022, 140 : 3726 - 3727
[32] The Effect of Low-Dose IL-2 in Clinical Facial Transplantation: Molecular and Immunological Response
Murakami, N.
Win, T.
Borges, T.
Lian, C.
Murphy, G.
Bueno, E.
Clark, R.
Strom, T.
Pomahac, B.
Riella, L.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 610 - 611
[33] INDUCTION OF REMISSION BY LOW-DOSE IL-2-THERAPY IN ONE SLE PATIENT WITH INCREASED DISEASE ACTIVITY REFRACTORY TO STANDARD THERAPIES
Humrich, J. Y.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 50 - 50
[34] Intraprostatic interleukin-2 (IL-2) gene therapy: Results of a phase I clinical trial for the treatment of locally advanced prostate cancer
Naitoh, J
Gillespie, D
Tso, CL
Kaboo, R
Stiles, A
Figlin, R
Belldegrun, A
[J]. CANCER GENE THERAPY, 1998, 5 (06) : S1 - S1
[35] Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
Whangbo, Jennifer S.
Kim, Haesook T.
Nikiforow, Sarah
Koreth, John
Alho, Ana C.
Falahee, Bryn
Kim, Soomin
Dusenbury, Katharine
Fields, Marie J.
Reynolds, Carol G.
Alyea, Edwin P., III
Armand, Philippe
Cutler, Corey S.
Ho, Vincent T.
Antin, Joseph H.
Soiffer, Robert J.
Ritz, Jerome
[J]. BLOOD ADVANCES, 2019, 3 (07) : 984 - 994
[36] INCREASED PERIPHERAL CD8+T CELL RESPONSES IN SLE BY LOW-DOSE IL-2 TREATMENT
Zhang, R.
He, J.
Sun, X.
Zou, Y.
Gan, Y.
Li, Z.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1065 - 1065
[37] Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer
Angevin, E
ValteauCouanet, D
Farace, F
Dietrich, PY
Lecesne, A
Triebel, F
Escudier, B
[J]. JOURNAL OF IMMUNOTHERAPY, 1995, 18 (03): : 188 - 195
[38] Low-Dose IL-2 Combined with Rapamycin Efficiently Promotes Remission of Refractory Systemic Lupus Erythematosus
Liang, Zhaoyun
Jing, Xiaona
Hao, Meihua
Gao, Chong
Li, Xiao-Feng
Chen, Junwei
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[39] Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
Sarkar, Nandita
Hu, Xuguang
Tchao, Nadia
Furie, Richard
Kivitz, Alan
Cohen, Stanley B.
Gorski, Kevin
[J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1957 - 1958
[40] REGULATORY T CELL DEFECTS IN SLE AND THERAPY WITH A NOVEL IL-2 MUTEIN: PHASE 1 CLINICAL RESULTS WITH EFAVALEUKIN ALFA
Sarkar, N.
Hu, X.
Tchao, N.
Furie, R.
Kivitz, A.
Cohen, S.
Gorski, K.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 92 - 93

← 1 2 3 4 5 →